跳至主要内容
临床试验/NCT07585786
NCT07585786尚未招募不适用

A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Renal Function in Patients With Liver Cirrhosis, Portal Hypertension Bleeding

Northern Jiangsu People's Hospital0 个研究点目标入组 30 人开始时间: 2026年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
主要终点
Serum creatinine (Scr) level

研究概览

简要总结

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

详细描述

Liver cirrhosis is associated with systemic hemodynamic disturbances, reduced effective circulating volume, and renal hypoperfusion, creating a high risk of renal dysfunction and hepatorenal syndrome (HRS)-a life-threatening condition reflecting the critical hepatorenal interaction. Patients with cirrhosis, Portal Hypertension Bleeding frequently have subclinical or overt renal impairment preoperatively. LSD is a standard intervention for Cirrhosis Patients With Portal Hypertension Bleeding, but perioperative stress, hemodynamic fluctuations, and surgical trauma may further compromise renal function, and LSD may improve kidney function in the long term. Current evidence lacks prospective, 2-year data on renal function changes after LS in this high-risk population, especially regarding the hepatorenal axis and long-term renal outcomes. This study aims to fill this gap to guide perioperative renal protection strategies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
  • •Splenomegaly and hypersplenism
  • •History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
  • •Age 18-80 years, male or female
  • •Child-Pugh Class A or B liver function
  • •No history of primary renal disease or acute kidney injury (AKI)
  • •Signed written informed consent
  • •Ability to complete 24-month follow-up

排除标准

  • •Child-Pugh Class C liver cirrhosis
  • •Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)
  • •Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection
  • •Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
  • •Hepatic encephalopathy or refractory ascites within 1 month before surgery
  • •Pregnancy or lactation
  • •Poor compliance, inability to complete follow-up

结局指标

主要结局

Serum creatinine (Scr) level

时间窗: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Change in serum creatinine (Scr) level

Glomerular filtration rate (eGFR)

时间窗: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Change in estimated glomerular filtration rate (eGFR). For females: If serum creatinine (Scr) ≤ 0.7 mg/dL: eGFR = 142 × (Scr/0.7)\^(-0.241) × (0.9938)\^Age; If Scr \> 0.7 mg/dL: eGFR = 142 × (Scr/0.7)\^(-1.200) × (0.9938)\^Age. For males: If Scr ≤ 0.9 mg/dL: eGFR = 142 × (Scr/0.9)\^(-0.302) × (0.9938)\^Age; If Scr \> 0.9 mg/dL: eGFR = 142 × (Scr/0.9)\^(-1.200) × (0.9938)\^Age. Note: Results are in mL/min/1.73 m². Age is in years.

BUN and UA level

时间窗: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Changes in BUN and UA level

Urine albumin-to-creatinine ratio (UACR)

时间窗: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Changes in urine albumin-to-creatinine ratio \[UACR (mg/g) = Urine albumin concentration (mg/L) ÷ Urine creatinine concentration (g/L)\]

次要结局

  • Intraoperative variables(During the procedure of operation)
  • Postoperative complications(at preoperative baseline, postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12, month 18, month 24)
  • Child-Pugh grade(at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24)
  • Albumin and bilirubin level(at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24)

研究者

发起方
Northern Jiangsu People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Guo-Qing Jiang

Clinical Professor

Northern Jiangsu People's Hospital

相似试验